- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 263/06 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
Patent holdings for IPC class C07D 263/06
Total number of patents in this class: 99
10-year publication summary
|
4
|
4
|
7
|
6
|
10
|
3
|
2
|
4
|
5
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Enzo Therapeutics, Inc. | 29 |
9 |
| Virginia Commonwealth University | 632 |
7 |
| Merck Sharp & Dohme Corp. | 2190 |
5 |
| Henkel AG & Co. KGaA | 10584 |
4 |
| Dong-A ST Co., Ltd. | 133 |
3 |
| Oncternal Therapeutics, Inc. | 36 |
3 |
| Baker Hughes Incorporated | 5238 |
2 |
| Angus Chemical Company | 105 |
2 |
| Daewoong Pharmaceutical Co., Ltd. | 325 |
2 |
| Enzo Biochem, Inc. | 126 |
2 |
| Nosopharm | 10 |
2 |
| Schering-Plough Ltd. | 18 |
2 |
| Sinclair Pharmaceuticals Limited | 62 |
2 |
| Tapestry Pharmaceuticals, Inc. | 26 |
2 |
| Cyclerion Therapeutics, Inc. | 78 |
2 |
| Nutrition & Biosciences USA 2, LLC | 79 |
2 |
| Merck Sharp & Dohme LLC | 3742 |
2 |
| The Procter & Gamble Company | 22035 |
1 |
| Novartis AG | 10829 |
1 |
| Genentech, Inc. | 3983 |
1 |
| Other owners | 43 |